Positron Expands on Its Entry into Radiation Detection Devices for Homeland Security Applications
Wednesday March 14, 12:37 pm ET
HOUSTON, Texas--(BUSINESS WIRE)--Positron Corporation (OTCBB:POSC - News), through its research and development affiliate, has filed a provisional patent on a device that is capable of detecting illicit radioactive sources at a distance. The processes and techniques utilized in the development of the radiation detection devices arose as a result of Positron's long history in the field of medical imaging and positron emission mammography ("PET") scanners. A PET ("Positron Emission Tomography") scanner is a sensitive radiation detection device that detects cancer-seeking radiopharmaceuticals injected into the human body. PET scanners operate at close distances to the body. Radiation detection devices for Homeland Security must be able to detect potential nuclear threats at much lower dose levels than used in PET and in a much shorter time period, from as far as 100 meters away.
The Positron team was led by Irving Weinberg M.D., Ph.D., and included a team of academic scientists working in the fields of medical imaging, nuclear non-proliferation, radiation surveillance, high energy physics, and program management. Dr. Weinberg was the inventor of two devices now commonly used for functional breast imaging of thousands of women annually (i.e., scintimammography and positron emission mammography). Dr. Weinberg was trained at the National Institutes of Health, the Johns Hopkins Hospital, and UCLA (where he worked with Dr. Ed Hoffman and Dr. Michael Phelps, the inventors of the PET scanner). Dr. Weinberg previously founded the first company to take advantage of the clinical abilities of high-resolution PET for organ-specific imaging (Naviscan PET Systems, Inc.), and to market these products to surgeons as well as radiologists. Dr. Weinberg's current effort has been to engineer a high-level upgrade of Positron's current PET scanner technology, and to discover new applications for these emerging products.
The new stand-off radiation scanner (SORAC) incorporates proprietary state-of-the-art solid-state photodetectors developed by the Positron affiliate's scientific team. These detectors are the key to the miniaturization and overall effectiveness of global nuclear detection architecture. Unlike competing technologies (i.e., High-Purity Germanium), the solid-state detectors do not require cooling, and hence have greater mobility and substantially lower power requirements. The photodetectors cost much less than conventional high-resolution components (e.g., multi-anode photomultipliers), which is an advantage for medical imaging as well as Homeland Security applications.
Positron plans to finance the future development of this unique concept toward commercialization through separate project financing.
Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology. Positron Corporation incorporates patented and proprietary software and hardware technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. Positron's PET systems are in use at leading medical facilities throughout North America and in select International markets. Additional information may be found at www.positron.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," and similar expressions are intended to identify such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (281) 492-7100.
|Home | Molecular Imaging | Affiliates | Opportunity | Investment | Press | News | About | Contact | Sitemap|